Skip to content

Helmet NIV in Acute Respiratory Failure

Helmet NIV Versus Facemask NIV in Acute Respiratory Failure: A Pilot Randomized Control Trial

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05022173
Acronym
HELMET
Enrollment
15
Registered
2021-08-26
Start date
2021-11-11
Completion date
2025-11-30
Last updated
2025-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Failure

Keywords

non-invasive ventilation, Helmet non-invasive ventilation

Brief summary

Non-invasive ventilation (NIV) is a form of respiratory support that has been shown to prevent invasive mechanical ventilation and reduce mortality. This study will investigate the feasibility of performing a larger study examining whether a new modality of NIV, the helmet, is superior to the current face mask in reducing mortality in patients with sudden respiratory failure.

Interventions

The helmet interface is a modality which is used to deliver NIV to patients with respiratory failure. A transparent hood is placed over the entire head of the patient with a seal at the neck using a soft collar.

DEVICEFacemask Non-Invasive Ventilation

The facemask interface is a modality which is also used to deliver NIV to patients with respiratory failure. A large mask covering the mouth and nose is strapped to the patient's face to create a seal.

Sponsors

Hamilton Health Sciences Corporation
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 1\) patients who are admitted to the adult ICU * 2\) deemed to require NIV, as per the clinical team, for acute respiratory failure.

Exclusion criteria

* 1\) with impending cardiac arrest or need for intubation * 2\) Glasgow coma scale \<9 * 3\) tracheostomy or upper airway obstruction * 4\) elevated intracranial pressure * 5\) untreated pneumothorax * 6\) who refuse endotracheal intubation (do not intubate order documented) * 7\) facial trauma * 8\) are unable to wear the helmet or facemask * 9\) who use NIV chronically

Design outcomes

Primary

MeasureTime frameDescription
Consent Rate1 yearPercentage of patients or SDMs approached for consent who give consent
Recruitment Rate1 yearNumber of patients recruited to the study per centre
Protocol adherence percentage1 yearAdherence to pre-specified fixed protocol on how helmet interface is implemented (settings, weaning etc.) Any protocol deviations will be recorded and marked as protocol non-adherence.

Secondary

MeasureTime frameDescription
ICU length of stayCensored at 28 daysNumber of days that each patient spends in ICU
Hospital length of stayCensored at 60 daysNumber of days that each patients spends in hospital
Duration of non-invasive ventilationCensored at 28 daysNumber of days that patient receives non-invasive ventilation
Endotracheal intubation28 daysNumber of patients requiring endotracheal intubation
Adverse events28 daysAny complications related to NIV use
Comfort28 daysPatient comfort with non-invasive ventilation
Duration of invasive ventilationCensored at 28 daysNumber of days that patient receives invasive ventilation
ICU mortality28 daysNumber of patients who die in ICU
Hospital mortality60 daysNumber of patients who die in hospital

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026